drugset / Trial / NCT02735603

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

NCT02735603

Phase 1 Completed 84 enrolled Orexigen Therapeutics, Inc
RandomizedCrossoverQuadruple-blind

Summary

The purpose of this study is to evaluate the potential effect of naltrexone and bupropion extended-release combination on cardiac repolarization in healthy participants.

Timeline

Start
2016-04
Primary completion
2016-07
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 180 mg Oral
Subject Moxifloxacin Small molecule 400 mg Oral
Subject Naltrexone Small molecule 16 mg Oral